|Bid||11.66 x 1000|
|Ask||12.39 x 1300|
|Day's range||11.50 - 12.05|
|52-week range||7.58 - 21.50|
|Beta (5Y monthly)||3.19|
|PE ratio (TTM)||N/A|
|Earnings date||19 Oct 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
STAFFORD, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to December 31, 2024 which is approximatel
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...